SeekingAlpha · Aug 13, 2026
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy
Harrow is upgraded to a cautious Buy on Q2 execution, VEVYE/IHEEZO momentum, and leverage. Click here to read my most recent analysis of HROW stock.
HR
NASDAQ · HROW
Harrow Health, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$42.06
Down-$1.11 (-2.64%)
Updated Aug 22, 2026, 1:43 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.89B
- P/E ratio
- -183.74
- Dividend yield
- 0.00%
- 52-week range
- $28.54 – $47.50
- Volume
- 450.07K
- Avg. volume
- 738.98K
Price performance
HROW price history
1M range · 20 trading sessions · Daily adjusted prices
HROW closed at $42.06 after 20 trading sessions, up 9.39% for the selected period.
- Last close
- $42.06
- Period change
- +9.39%
- Period low
- $37.46
- Period high
- $42.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $41.64 | $42.71 | $41.24 | $42.06 | 450.07K |
| Aug 19, 2026 | $39.95 | $42.30 | $39.67 | $41.64 | 651.74K |
| Aug 18, 2026 | $39.26 | $40.14 | $38.21 | $39.52 | 920.43K |
| Aug 17, 2026 | $39.21 | $40.32 | $39.0512 | $39.475 | 323.38K |
| Aug 14, 2026 | $39.21 | $41.235 | $38.87 | $40.03 | 513.31K |
| Aug 13, 2026 | $39.58 | $40.895 | $38.27 | $38.87 | 516.47K |
| Aug 12, 2026 | $40.25 | $40.9552 | $39.02 | $39.36 | 805.01K |
| Aug 11, 2026 | $39.00 | $42.999 | $37.70 | $39.42 | 1.91M |
| Aug 10, 2026 | $40.47 | $41.076 | $39.6439 | $40.70 | 803.91K |
| Aug 7, 2026 | $39.97 | $41.1207 | $39.845 | $40.44 | 322.86K |
| Aug 6, 2026 | $40.15 | $40.645 | $39.25 | $39.92 | 333.6K |
| Aug 5, 2026 | $39.89 | $40.60 | $39.22 | $39.41 | 301.81K |
| Aug 4, 2026 | $39.15 | $39.98 | $39.11 | $39.83 | 368.34K |
| Aug 3, 2026 | $38.51 | $39.14 | $38.00 | $39.09 | 400.52K |
| Jul 31, 2026 | $38.86 | $39.01 | $37.18 | $38.77 | 261.66K |
| Jul 30, 2026 | $38.68 | $39.64 | $38.49 | $38.94 | 291.06K |
| Jul 29, 2026 | $38.84 | $39.72 | $38.38 | $38.68 | 362.73K |
| Jul 28, 2026 | $37.46 | $39.38 | $36.25 | $39.32 | 569.63K |
| Jul 27, 2026 | $39.162 | $39.93 | $37.36 | $37.46 | 516.68K |
| Jul 24, 2026 | $42.30 | $42.30 | $38.11 | $38.45 | 888.66K |
Latest HROW news
The latest Smart Investors Daily articles mentioning HROW.
Stock researchCompany · Overview
HROW research
Overview
Company profile and research snapshot.
Company profile
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $73.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 21, 2026 | BTIG | Buy | — |
| May 13, 2026 | Cantor Fitzgerald | Overweight | — |
| May 12, 2026 | BTIG | Buy | — |
| Apr 17, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 11, 2026
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow, Inc. (HROW) Q2 2026 Earnings Call August 11, 2026 8:00 AM EDTCompany ParticipantsMichael Biega - Vice President of Investor Relations &...
Benzinga · Aug 11, 2026
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
BTIG analyst Thomas Shrader reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $63 price target.
Benzinga · Aug 10, 2026
Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M Est
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $348.468 million estimate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
